Biocon subsidiary Syngene and Bristol-Myers Squibb new research facility to come in "Biocon Park"

Biocon Ltd has announced that the Company's wholly owned subsidiary Syngene International Pvt Ltd and global pharma major Bristol-Myers Squibb (NYSE: BMY) conducted the ground breaking ceremony of their new research facility at Biocon Park on March 21, 2007.

Dr. Francis Cuss, Senior Vice President, Pharmaceutical Research Institute, Bristol Myers Squibb laid the foundation stone. Dr. Kiran Mazumdar-Shaw Chairman of the Biocon Group and Syngene's Chief Operating Officer, Dr. Goutam Das were also present.

The research facility at Biocon Park is located at the Company's new facility 'Biocon Park'. Bommasandra Industrial Area - Phase IV (approx 4 kms from the Company). Spread over approximately 150,000 sq feet, the facility is planned to ultimately house more than 400 scientists to help advance Bristol-Myers Squibb's discovery and early drug development in India. This is expected to significantly increase the scope of Bristol Myers Squibb's existing relationship with Biocon’s Syngene to further develop integrated capabilities in medicinal chemistry, biology, drug metabolism and pharmaceutical development.

Biocon, a symbol of the biotech success story of India, has delivered products and solutions in the field of Bio-Pharmaceuticals to customers across the globe.

Source : Equity Bulls

Keywords